Synergistic Drug Combinations for Tuberculosis Therapy Identified by a Novel High-throughput Screen

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2011 May 18

PMID 21576426

Citations 55

Authors

Santiago Ramon-Garcia

Carol Ng

Hilary Anderson

Joseph D Chao

Xingji Zheng

Tom Pfeifer

Yossef Av-Gay

Michel Roberge

Charles J Thompson

Affiliations

Soon will be listed here.

Abstract

Therapeutic options for tuberculosis (TB) are limited and notoriously ineffective despite the wide variety of potent antibiotics available for treating other bacterial infections. We investigated an approach that enables an expansion of TB therapeutic strategies by using synergistic combinations of drugs. To achieve this, we devised a high-throughput synergy screen (HTSS) of chemical libraries having known pharmaceutical properties, including thousands that are clinically approved. Spectinomycin was used to test the concept that clinically available antibiotics with limited efficacy against Mycobacterium tuberculosis might be used for TB treatment when coadministered with a synergistic partner compound used as a sensitizer. Screens using Mycobacterium smegmatis revealed many compounds in our libraries that acted synergistically with spectinomycin. Among them, several families of antimicrobial compounds, including macrolides and azoles, were also synergistic against M. tuberculosis in vitro and in a macrophage model of M. tuberculosis infection. Strikingly, each sensitizer identified for synergy with spectinomycin uniquely enhanced the activities of other clinically used antibiotics, revealing a remarkable number of unexplored synergistic drug combinations. HTSS also revealed a novel activity for bromperidol, a butyrophenone used as an antipsychotic drug, which was discovered to be bactericidal and greatly enhanced the activities of several antibiotics and drug combinations against M. tuberculosis. Our results suggest that many compounds in the currently available pharmacopoeia could be readily mobilized for TB treatment, including disease caused by multi- and extensively drug-resistant strains for which there are no effective therapies.

Citing Articles

Heterocyclic Antidepressants with Antimicrobial and Fungicide Activity.

Zolotareva D, Zazybin A, Belyankova Y, Bayazit S, Dauletbakov A, Seilkhanov T Molecules. 2025; 30(5).

PMID: 40076325 PMC: 11902072. DOI: 10.3390/molecules30051102.

«Green-Ligand» in Metallodrugs Design-Cu(II) Complex with Phytic Acid: Synthetic Approach, EPR-Spectroscopy, and Antimycobacterial Activity.

Koshenskova K, Makarenko N, Dolgushin F, Yambulatov D, Bekker O, Fedin M Molecules. 2025; 30(2).

PMID: 39860183 PMC: 11767443. DOI: 10.3390/molecules30020313.

Targeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives.

Mubarak M, Kantroo H, Mir F, Kumar C, Ahmad Z Arch Microbiol. 2025; 207(2):34.

PMID: 39812792 DOI: 10.1007/s00203-025-04238-x.

Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.

Ramon-Garcia S, Gonzalez Del Rio R, Arenaz-Callao M, Boshoff H, Rullas J, Anca S bioRxiv. 2025; .

PMID: 39803560 PMC: 11722294. DOI: 10.1101/2024.10.10.617558.

Identification of gene targets that potentiate the action of rifampicin on BCG.

Chand P, Mendum T, Butler R, Hingley-Wilson S, Stewart G Microbiology (Reading). 2024; 170(8).

PMID: 39150447 PMC: 11329110. DOI: 10.1099/mic.0.001488.

References

Zhang L, Yan K, Zhang Y, Huang R, Bian J, Zheng C . High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc Natl Acad Sci U S A. 2007; 104(11):4606-11. PMC: 1838648. DOI: 10.1073/pnas.0609370104. View

Nguyen L, Thompson C . Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol. 2006; 14(7):304-12. DOI: 10.1016/j.tim.2006.05.005. View

Payne D, Gwynn M, Holmes D, Pompliano D . Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2006; 6(1):29-40. DOI: 10.1038/nrd2201. View

Sun J, Lau A, Wang X, Liao T, Zoubeidi A, Hmama Z . A broad-range of recombination cloning vectors in mycobacteria. Plasmid. 2009; 62(3):158-65. DOI: 10.1016/j.plasmid.2009.07.003. View

Benfield P, Ward A, Clark B, Jue S . Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. Drugs. 1988; 35(6):670-84. DOI: 10.2165/00003495-198835060-00004. View

Jassal M, Bishai W . Extensively drug-resistant tuberculosis. Lancet Infect Dis. 2008; 9(1):19-30. DOI: 10.1016/S1473-3099(08)70260-3. View

Chiang C, Centis R, Migliori G . Drug-resistant tuberculosis: past, present, future. Respirology. 2010; 15(3):413-32. DOI: 10.1111/j.1440-1843.2010.01738.x. View

Ramon-Garcia S, Martin C, Ainsa J, De Rossi E . Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J Antimicrob Chemother. 2005; 57(2):252-9. DOI: 10.1093/jac/dki436. View

Novak E, Gray J, Pfeifer R . Animal and human tolerance of high-dose intramuscular therapy with spectinomycin. J Infect Dis. 1974; 130(1):50-5. DOI: 10.1093/infdis/130.1.50. View

10.

Koul A, Arnoult E, Lounis N, Guillemont J, Andries K . The challenge of new drug discovery for tuberculosis. Nature. 2011; 469(7331):483-90. DOI: 10.1038/nature09657. View

11.

. Handbook of anti-tuberculosis agents. Introduction. Tuberculosis (Edinb). 2008; 88(2):85-6. DOI: 10.1016/S1472-9792(08)70002-7. View

12.

Yeh P, Tschumi A, Kishony R . Functional classification of drugs by properties of their pairwise interactions. Nat Genet. 2006; 38(4):489-94. DOI: 10.1038/ng1755. View

13.

Hugonnet J, Tremblay L, Boshoff H, Barry 3rd C, Blanchard J . Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science. 2009; 323(5918):1215-8. PMC: 2679150. DOI: 10.1126/science.1167498. View

14.

Diacon A, Patientia R, Venter A, Van Helden P, Smith P, McIlleron H . Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007; 51(8):2994-6. PMC: 1932511. DOI: 10.1128/AAC.01474-06. View

15.

Ouellet H, Johnston J, de Montellano P . The Mycobacterium tuberculosis cytochrome P450 system. Arch Biochem Biophys. 2009; 493(1):82-95. PMC: 2812603. DOI: 10.1016/j.abb.2009.07.011. View

16.

Kohanski M, Dwyer D, Hayete B, Lawrence C, Collins J . A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007; 130(5):797-810. DOI: 10.1016/j.cell.2007.06.049. View

17.

Johnson M, MacDougall C, Ostrosky-Zeichner L, Perfect J, Rex J . Combination antifungal therapy. Antimicrob Agents Chemother. 2004; 48(3):693-715. PMC: 353116. DOI: 10.1128/AAC.48.3.693-715.2004. View

18.

Yasui-Furukori N, Kondo T, Ishida M, Furukori H, Suzuki A, Kaneko S . Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26(1):53-7. DOI: 10.1016/s0278-5846(01)00218-4. View

19.

Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Palomino J . Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2005; 55(4):500-5. DOI: 10.1093/jac/dki023. View

20.

Chong C, Sullivan Jr D . New uses for old drugs. Nature. 2007; 448(7154):645-6. DOI: 10.1038/448645a. View